Replicel
Collapse
X
-
-
RepliCel has zip, zero, zilch, nada. They are a total failure and will never amount to anything. They are not an adapting or innovating company. They went all on on DSCC being the answer, and of course, as we know, its not. DSCC is all they got. The reason they are presenting is to try to stir up investor interest, as raising money is now an impossible task as their product looks hopeless and their share price has fallen to bellow $.50/share.
RepliCel, stick a fork in them, they're done.Comment
-
I believe there is potential for such developments even if these products are subpar compared to what they are supposed to do. Just a gut feeling.Comment
-
It would put me in mind of the tail wagging the dog scenario, if its the case. Anyway, we'll see.Comment
-
I wonder if the principal shareholders are selling any of thier stock? Now that would be telling. I think the price was driven down by the less-than-touted stellar results obviously, but as much by a timid few who figured the apocolypse was nigh... OTCBB aint the "big board" as we know.
It would put me in mind of the tail wagging the dog scenario, if its the case. Anyway, we'll see.Comment
-
Lets not speculate just yet. NO ONE here on this forum has any inside information regarding this company or the others.
If Replicel's treatments can give you a good % more than what is currently available today ,even IF it is not the 'Holy Grail' in hair treatments,
people will rush to it ... David Hall will give his presentation on Monday the 25th of this month.Comment
-
I concur totally hellouser. If Replicel has it, it will show up in phase II. They scored a 19% in thier safety run, where they uber dosed all the subjects. They only wanted a peek at efficacy. Good peek, I'd say. That's why they are still alive. To think they will look for funding whilst having nothing is untenable. Check the resumes of these guys. This isn't Joe's Hair Shop. This next phase looks to mix it up with dosages, depths, relative distances and God knows what else, all with the grace of the competent authority. To say they are caput is unfounded whinery, I think.Comment
-
I concur totally hellouser. If Replicel has it, it will show up in phase II. They scored a 19% in thier safety run, where they uber dosed all the subjects. They only wanted a peek at efficacy. Good peek, I'd say. That's why they are still alive. To think they will look for funding whilst having nothing is untenable. Check the resumes of these guys. This isn't Joe's Hair Shop. This next phase looks to mix it up with dosages, depths, relative distances and God knows what else, all with the grace of the competent authority. To say they are caput is unfounded whinery, I think.Comment
-
The Phase II clinical trial represents a significant advance in the research. In the Phase I clinical trial, the company produced only 16 “data points.” The Phase II trial aims at 288, enough to determine the optimal type and amount of injections for treating hair loss.
The Vancouver, B.C.-based company says it has won patents for its technology from both the European Union and Australia and that patents are currently pending in other jurisdictions.
“The Company has made significant advancements in its manufacturing procedures and these improvements are expected to have a meaningful impact on our RCH-01 program,” said Replicel CEO David Hall, in a written statement released in early February. “We are committed to receiving guidance and implementing the recommendations provided by the regulatory authorities to ensure we have a well-constructed Phase II trial that will lead to the optimum dose to treat pattern baldness.”
So in a statement David Hall announced that changes have been made to the manufacturing procedure, this could have significant impact on the results. People have counted Replicel out but at the end of the day they have taken on board there unsatisfactory results in regards to efficacy and they have made changes before continuing - the most probable reason as to why they're now about 9 months behind on their estimated start of Phase II.
I also agree with others, phase II is the dosing trial, they can try different doses, depths and frequency of injections. This trial will let us know if this is compoundable and if it is then that makes even the current efficacy results more promising.
I can't believe that they would be progressing unless they had some hope of better results, there was a lot of promise when Replicel first started trials so lets hope the phase II trials surprises us all with much better results.Comment
Comment